newsfilter
← Latest News
GlobeNewswire·

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r) multiple myeloma (MM) In July 2022, the U.S. Food and Drug Administration (FDA) lifted the clinical